In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca's failed heart disease trial sparks debate about RNA drugs' effectiveness
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 3.
Source diversity sample: Fierce Pharma · Yahoo Finance · Medical Xpress · BioPharma Dive · HCPLive.
How this dossier is built: methodology · AI policy · corrections.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
AstraZeneca and Ionis Pharmaceuticals released full data from a failed trial of eplontersen, an RNA drug designed to treat transthyretin-mediated amyloid cardiomyopathy. The drug did not meet its primary endpoint, leading to a drop in both companies' stock prices.
The trial's failure has sparked a broader debate about the potential of RNA drugs in treating deadly heart diseases. The CARDIO-TTRansform trial was designed to test eplontersen's ability to reduce cardiovascular-related deaths and hospitalizations in patients with transthyretin-mediated amyloid cardiomyopathy.
The results, published in Medical Xpress and HCPLive, indicate that the drug did not achieve the desired outcomes. BioPharma Dive noted that the failure has raised questions about the future of RNA drugs in cardiovascular treatments.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 4h ago.
Coverage (5)
- ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM Fierce Pharma · 1d ago
- IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial Yahoo Finance · 1d ago
- Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy Medical Xpress · 1d ago
- AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease BioPharma Dive · 1d ago
- CARDIO-TTRansform: Eplontersen Misses Primary Endpoint in ATTR-CM HCPLive · 1d ago
The obvious questions
What is eplontersen?
Eplontersen is an RNA drug developed by AstraZeneca and Ionis Pharmaceuticals to treat transthyretin-mediated amyloid cardiomyopathy.
What was the primary endpoint of the CARDIO-TTRansform trial?
The primary endpoint was to reduce cardiovascular-related deaths and hospitalizations in patients with transthyretin-mediated amyloid cardiomyopathy.
How did the stock prices of AstraZeneca and Ionis Pharmaceuticals react to the trial results?
Both companies' stock prices fell following the release of the full trial data.
Topics
From around our network
- Women and Heart Disease: Symptoms, Risks, and Myths to Ignore world-today-news.com
Related trends
The common heart attack symptom many women ignore
Heart disease is the leading cause of death in women, but many women ignore a common symptom of heart attack.
SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
A major clinical trial has found that oral anticoagulants reduce stroke risk in atrial fibrillation patients at intermediate risk, despite increased bleeding.
Alnylam’s heart drug troubles take center stage at a cardiology conference
AstraZeneca's failed heart disease drug trial is raising questions about the future of gene silencer drugs.
Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial
A first clinical trial shows promise for a new cell therapy to treat severe rheumatoid arthritis.
AI can detect heart disease in women using mammograms, study suggests
AI may let routine breast scans flag women's heart disease years before symptoms appear.
Calcium heart scans sharpen risk estimates mainly for borderline-risk adults
A $100 heart scan could help some adults decide whether to start taking statins.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.